Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPRS1 | P07814 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | HAAO | P46952 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30993669 | 1.00 | EPRS1 (0.41) | EPRS1CYP1A2ADRA2ACLCN2ALB | |
| SCHEMBL852651 | 0.84 | EPRS1 (0.44) | EPRS1CYP1A2ADRA2ACLCN2ALB | |
| SCHEMBL31094955 | 0.81 | CYP1A2 (0.44) | CYP1A2ALBCES2CES1TSHR | |
| SCHEMBL14472134 | 0.81 | CYP1A2 (0.44) | EPRS1CYP1A2ADRA2ACLCN2ALB | |
| SCHEMBL9277089 | 0.79 | NPC1 (0.42) | CES2CES1TSHRCASP1SMN1; SMN2 | |
| SCHEMBL286718 | 0.79 | HAAO (0.42) | CYP1A2RXFP1TSHRNOTUMHAAO | |
| SCHEMBL29975434 | 0.79 | CES2 (0.45) | CYP1A2ALBCES2CES1TSHR | |
| SCHEMBL107175 | 0.79 | CES2 (0.50) | EPRS1CYP1A2ADRA2ACLCN2ALB | |
| SCHEMBL29465861 | 0.79 | CES2 (0.50) | EPRS1CYP1A2ADRA2ACLCN2ALB | |
| SCHEMBL3980826 | 0.79 | CYP1A2 (0.42) | EPRS1CYP1A2RXFP1TSHRHAAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137158-A1 | DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20240325547-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024130095-A9 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-02 | — | — | WO | disclosed |
| CN-118388454-A | Modulators of BCL6 proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118359538-A | Isoquinoline compound, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| US-11986532-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4323352-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| EP-1606269-B1 | BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO INC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
| US-7326726-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20060183897-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. | 2006-08-17 | — | — | US | disclosed |
| WO-2006051390-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHODS OF PREPARING THEM | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-05-18 | — | — | WO | disclosed |
| CN-1747936-A | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA INC (US) | 2006-03-15 | — | — | CN | disclosed |
| EP-1606269-A1 | BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050119261-A1 | Biaryl substituted triazoles as sodium channnel blockers | MERCK SHARP & DOHME LLC | 2005-06-02 | — | — | US | disclosed |
| WO-2004083189-A1 | BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083190-A1 | BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | SCN3A, TRPV1, SCN1B | EPRS1 4820/4885CYP1A2 630/4885ADRA2A 226/4885 |
| US-11986532-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | EPRS1 1499/4885CYP1A2 4721/4885ADRA2A 4792/4885 |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | EPRS1 2360/4885CYP1A2 1502/4885ADRA2A 2979/4885 |
| US-20050119261-A1 | Biaryl substituted triazoles as sodium channnel blockers | SCN3A, TRPV1, KCNN3 | EPRS1 4765/4885CYP1A2 615/4885ADRA2A 218/4885 |
| US-20060183897-A1 | Biaryl substituted triazoles as sodium channel blockers | SCN3A, TRPV1, SCN1B | EPRS1 4820/4885CYP1A2 630/4885ADRA2A 226/4885 |
| US-20240325547-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | EPRS1 1499/4885CYP1A2 4721/4885ADRA2A 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.